Editing Ranbaxy Laboratories (section)

==History==

===Formation===
Ranbaxy was started by Ranbir Singh and Gurbax Singh in 1937 as a distributor for Japanese company [[Shionogi]]. The name Ranbaxy blends the names of its founders: '''Ran'''bir and Gur'''bax'''. Bhai Mohan Singh bought the company in 1952 from his cousins Ranbir and Gurbax. After Bhai Mohan Singh's son Parvinder Singh joined the company in 1967, the company saw an increase in scale.

In the late 1990s, Ranbaxy formed a US company, Ranbaxy Pharmaceuticals Inc., in order to support its entry into the pharmaceutical market in United States.<ref>{{cite journal | url = https://www.pharmacytimes.com/publications/supplement/2013/generic-supplement-2013/ranbaxy-ranbaxy-continues-to-add-value-and-utility-to-us-product-portfolio | publisher = Pharmacy Times | website = pharmacytimes.com | title = Ranbaxy: Ranbaxy Continues to Add Value and Utility to US Product Portfolio | series = Generic Supplement 2013 | date = 23 July 2013 | quote = ''Ranbaxy [..] entered the U.S. generic pharmaceutical market in 1995 introducing its first product under the Ranbaxy Pharmaceuticals Inc. label in January 1998'' | access-date = 11 August 2018 | archive-date = 6 August 2020 | archive-url = https://web.archive.org/web/20200806135011/https://www.pharmacytimes.com/publications/supplement/2013/generic-supplement-2013/ranbaxy-ranbaxy-continues-to-add-value-and-utility-to-us-product-portfolio | url-status = dead }}</ref>

===Trading===
For the twelve months ending on 31 December 2005, the company's global sales were US$1,178 million, with overseas markets accounting for 75% of global sales (USA: 28%, Europe: 17%, Brazil, Russia, and China: 29%).{{citation needed|date=August 2018}}

In December 2005, Ranbaxy's share price was hit by a patent ruling disallowing production of its own version of [[Pfizer]]'s [[cholesterol]]-cutting drug [[Lipitor]], which had annual sales of more than $10 billion.<ref>[http://news.bbc.co.uk/2/hi/business/4542358.stm Patent ruling hits Ranbaxy shares]. BBC News (19 December 2005).</ref> 

In June 2008, Ranbaxy settled the patent dispute with Pfizer, allowing them to sell [[atorvastatin calcium]], the [[generic version]] of Lipitor and atorvastatin calcium-amlodipine besylate, the generic version of Pfizer's [[Caduet]], in the US, starting on 30 November 2011.{{Citation needed|date=May 2009}}

On 23 June 2006, the US [[Food & Drug Administration]] granted Ranbaxy a 180-day exclusivity period to sell [[simvastatin]] ([[Zocor]]) in the US as a [[generic drug]] at 80&nbsp;mg strength. Ranbaxy competed with the maker of brand-name Zocor, [[Merck & Co.]]; IVAX Corporation (which was acquired by and merged into Teva Pharmaceutical Industries Ltd.), which has 180-day exclusivity at strengths other than 80&nbsp; mg; and [[Dr. Reddy's Laboratories]] and India, whose authorized generic version (licensed by Merck) is exempt from exclusivity.{{citation needed|date=January 2016}}

On 1 December 2011, Ranbaxy got approval from the FDA to launch the generic version of Lipitor in the United States after the drug's patent expired.<ref>{{Cite web |url=https://www.bloomberg.com/businessweek/news/2011-11-30/ranbaxy-s-lipitor-copy-approved-by-fda-threatening-pfizer-sales.html | title = Ranbaxys lipitor copy approved by fda threatening pfizer sales |website=[[Bloomberg News]] |access-date=5 October 2020 }}</ref><ref>{{cite news| url=http://timesofindia.indiatimes.com/business/india-business/Ranbaxy-gets-approval-to-launch-generic-Lipitor-in-US/articleshow/10940626.cms | work=The Times of India | title=Ranbaxy gets approval to launch generic Lipitor in US – The Times of India}}</ref>

=== Acquisition by Daiichi Sankyo ===

In June 2008, [[Daiichi Sankyo]] acquired a 34.8% stake in Ranbaxy from the family of CEO and Managing Director [[Malvinder Mohan Singh]] for [[Indian Rupee|{{INR}}]] 10,000 [[crore]] (US$2.4 billion) at {{INR}}737 per share.<ref name="Wharton20080612">{{cite web |last1=Staff |title=The Ranbaxy-Daiichi Deal: Good Medicine, or a Harbinger of Future Ills? - Knowledge@Wharton |url=http://knowledge.wharton.upenn.edu/article/the-ranbaxy-daiichi-deal-good-medicine-or-a-harbinger-of-future-ills/ |website=Knowledge@Wharton |publisher=[[Wharton School]] |access-date=2018-08-11 |date=12 June 2008}}</ref><ref>{{Cite web|url=http://www.pharmaexhibition.com/Exhibit/Ranbaxy-Laboratories-Limited/India/Home|archive-url=https://archive.today/20130131175140/http://www.pharmaexhibition.com/Exhibit/Ranbaxy-Laboratories-Limited/India/Home|url-status=dead|title=Ranbaxy joined "Online Pharma Exhibition"|archive-date=31 January 2013}}</ref>

In November 2008, [[Daiichi-Sankyo]] completed the takeover of the company from the founding Singh family in a deal worth $4.6 billion{{Dubious|reason=This doesn't agree with the more complicated deal described (in future tense) in the Bloomberg article. Fix. |date=August 2018}}<ref>[https://web.archive.org/web/20110612111139/http://business.timesonline.co.uk/tol/business/industry_sectors/health/article4115884.ece TimesOnlineUK – Business – Takeover of Ranbaxy]</ref> by acquiring a 63.92% stake in Ranbaxy. Ranbaxy's [[Malvinder Mohan Singh|Malvinder Singh]] remained as CEO after the transaction.<ref>Matsuyama, Kanoko. (11 June 2008) [https://www.bloomberg.com/apps/news?pid=newsarchive&sid=aMiwVweIVD60 Daiichi to Take Control of Ranbaxy for $4.6 Billion – 11 June 2008]. Bloomberg.</ref>
The addition of Ranbaxy Laboratories extended Daiichi-Sankyo's operations, with the combined company worth about US$30 billion.<ref>{{Cite news|title = Japanese drugmaker Daiichi Sankyo gobbles Ranbaxy Laboratories for $4.6 billion|date = 12 June 2008|archive-date = 16 November 2009|url = http://www.ibtimes.co.in/articles/20080612/ranbaxy-laboratories-daiichi-sankyo-generic-drug-pharmaceutical-takeover-acquisition-malvinder-singh.htm|archive-url = https://web.archive.org/web/20091116192726/http://www.ibtimes.co.in/articles/20080612/ranbaxy-laboratories-daiichi-sankyo-generic-drug-pharmaceutical-takeover-acquisition-malvinder-singh.htm|first = Surojit|last = Chatterjee|work = [[International Business Times]]|location = New York}}</ref>

In 2009, it was reported that former [[Novartis]] Senior Vice-President Yugal Sikri would lead the Indian operations of Ranbaxy Laboratories.<ref>{{cite web |url=http://www.ranbaxy.com/common/ContactRegion.aspx?id=59&flag= |title=Ranbaxy Laboratories Limited > Contact Us > Worldwide Operations > India |publisher=Ranbaxy.com |url-status=dead |archive-url=https://web.archive.org/web/20120404065634/http://www.ranbaxy.com/common/ContactRegion.aspx?id=59&flag= |archive-date=4 April 2012}}</ref><ref>{{cite web|author=ET Bureau |url=http://articles.economictimes.indiatimes.com/2009-09-11/news/27658542_1_japanese-company-daiichi-sankyo-ranbaxy-laboratories-yugal-sikri |archive-url=https://web.archive.org/web/20130906115812/http://articles.economictimes.indiatimes.com/2009-09-11/news/27658542_1_japanese-company-daiichi-sankyo-ranbaxy-laboratories-yugal-sikri |url-status=dead |archive-date=6 September 2013 |title=Yugal Sikri to be New India CEO of Ranbaxy |work=The Economic Times |date=11 September 2009}}</ref>

In 2011, Ranbaxy Global Consumer Health Care received the OTC Company of the year award. 

In 2012, 2013, and 2014 Brand Trust Reports, Ranbaxy was ranked 161st, 225th, and 184th respectively among India's most trusted brands.<ref>{{Cite web|url =http://www.trustadvisory.info/allindia_2014.html|title =India's Most Trusted Brands 2014|publisher =Trust Research Advisory|url-status =dead|archive-url =https://web.archive.org/web/20150502221904/http://www.trustadvisory.info/allindia_2014.html|archive-date =2 May 2015}}</ref>

=== Acquisition by Sun Pharmaceutical ===

On 7 April 2014, India-based [[Sun Pharmaceutical]] and Japan-based Daiichi Sankyo jointly announced the sale of the entire 63.4% share of Ranbaxy from [[Daiichi Sankyo]] to Sun Pharmaceutical in a $4 billion all-share deal. Under these agreements, shareholders of Ranbaxy were to receive a 0.8 share of Sun Pharmaceutical for each share of Ranbaxy.<ref name="bp">{{cite web|title=Sun Pharma to acquire Ranbaxy for $4 billion in all-share deal|url=http://news.biharprabha.com/2014/04/sun-pharma-to-acquire-ranbaxy-for-4-billion-in-all-share-deal/|agency=Indo-Asian News Service|publisher=news.biharprabha.com|access-date=7 April 2014}}</ref> After this acquisition, the partner [[Daiichi-Sankyo]] was to hold a stake of 9% in Sun Pharmaceutical.<ref>{{cite web|url=https://www.bloomberg.com/news/2014-04-06/sun-pharmaceuticals-to-buy-india-s-ranbaxy-in-4-billion-deal.html|title=India's Sun Pharma to Buy Ranbaxy in $4 Billion Deal|website=[[Bloomberg News]]|access-date=2014-04-06}}</ref>